ABL-102

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameABL-102

Drug Alias NameABL-102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonistsT lymphocytes stimulantsInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists

TargetsTumor necrosis factor receptor superfamily member 9Inactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsSolid tumoursHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A